Cerus (NASDAQ:CERS) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.
A number of other analysts have also recently commented on CERS. Zacks Investment Research cut Cerus from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. ValuEngine upgraded Cerus from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 1st. Cantor Fitzgerald reiterated a “reduce” rating and set a $9.00 price objective on shares of Cerus in a research report on Friday, July 20th. Finally, Cowen set a $10.00 price objective on Cerus and gave the company a “buy” rating in a research report on Friday, August 3rd. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $8.13.
Cerus stock opened at $7.33 on Friday. The firm has a market cap of $1.04 billion, a P/E ratio of -13.09 and a beta of 1.60. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.03 and a quick ratio of 4.57. Cerus has a one year low of $2.43 and a one year high of $8.05.
Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $15.42 million during the quarter, compared to analysts’ expectations of $13.58 million. Cerus had a negative return on equity of 82.60% and a negative net margin of 76.37%. Cerus’s revenue for the quarter was up 61.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.16) earnings per share. research analysts anticipate that Cerus will post -0.44 earnings per share for the current year.
In other Cerus news, insider Richard J. Benjamin sold 35,416 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $7.20, for a total value of $254,995.20. Following the completion of the sale, the insider now owns 35,416 shares in the company, valued at $254,995.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kevin Dennis Green sold 50,000 shares of the company’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $7.50, for a total value of $375,000.00. Following the completion of the sale, the chief financial officer now owns 110,825 shares of the company’s stock, valued at approximately $831,187.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 88,199 shares of company stock valued at $649,365. Company insiders own 6.80% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CERS. Rhumbline Advisers increased its position in Cerus by 10.9% in the first quarter. Rhumbline Advisers now owns 107,397 shares of the biotechnology company’s stock worth $589,000 after buying an additional 10,580 shares in the last quarter. Swiss National Bank increased its position in Cerus by 20.3% in the first quarter. Swiss National Bank now owns 221,900 shares of the biotechnology company’s stock worth $1,216,000 after buying an additional 37,500 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Cerus by 27.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 627,912 shares of the biotechnology company’s stock worth $3,441,000 after buying an additional 136,003 shares in the last quarter. Alambic Investment Management L.P. purchased a new stake in Cerus in the first quarter worth about $225,000. Finally, Northern Trust Corp increased its position in Cerus by 10.4% in the first quarter. Northern Trust Corp now owns 1,462,663 shares of the biotechnology company’s stock worth $8,015,000 after buying an additional 138,190 shares in the last quarter. Institutional investors and hedge funds own 59.77% of the company’s stock.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
See Also: Do Tariffs Work?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.